243 related articles for article (PubMed ID: 32621944)
1. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.
Hagström H; Talbäck M; Andreasson A; Walldius G; Hammar N
J Hepatol; 2020 Nov; 73(5):1023-1029. PubMed ID: 32621944
[TBL] [Abstract][Full Text] [Related]
2. Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease.
Hagström H; Talbäck M; Andreasson A; Walldius G; Hammar N
Gastroenterology; 2020 Jan; 158(1):200-214. PubMed ID: 31563624
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
5. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
6. Improved prediction of 10-year risk of severe liver disease in the general population using commonly available biomarkers.
Hagström H; Yan J; Talbäck M; Andreasson A; Walldius G; Bottai M; Hammar N
Aliment Pharmacol Ther; 2023 Feb; 57(4):418-425. PubMed ID: 36566508
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
[TBL] [Abstract][Full Text] [Related]
9. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
Cholankeril G; Kramer JR; Chu J; Yu X; Balakrishnan M; Li L; El-Serag HB; Kanwal F
J Hepatol; 2023 Mar; 78(3):493-500. PubMed ID: 36402450
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
12. Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis.
Jung CH; Rhee EJ; Kwon H; Chang Y; Ryu S; Lee WY
Endocrinol Metab (Seoul); 2020 Mar; 35(1):165-176. PubMed ID: 32207277
[TBL] [Abstract][Full Text] [Related]
13. Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease - A Population-based Cohort Study.
Ebrahimi F; Simon TG; Hagström H; Söderling J; Wester A; Roelstraete B; Ludvigsson JF
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3346-3355.e19. PubMed ID: 37245712
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.
Wijarnpreecha K; Thongprayoon C; Scribani M; Ungprasert P; Cheungpasitporn W
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):404-410. PubMed ID: 29215435
[TBL] [Abstract][Full Text] [Related]
15. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
[TBL] [Abstract][Full Text] [Related]
16. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
17. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
[TBL] [Abstract][Full Text] [Related]
18. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
19. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.
Simon TG; Henson J; Osganian S; Masia R; Chan AT; Chung RT; Corey KE
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2776-2784.e4. PubMed ID: 31077838
[TBL] [Abstract][Full Text] [Related]
20. Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups.
Sugiyama A; Kurisu A; E B; Ouoba S; Ko K; Rakhimov A; Akita T; Harakawa T; Sako T; Koshiyama M; Kumada T; Tanaka J
BMC Gastroenterol; 2022 May; 22(1):241. PubMed ID: 35562658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]